Effect of Clinical and Biochemical Variables Over Morbidity and Mortality in Alcohol Withdrawal Syndrome Patients

Last updated: September 9, 2024
Sponsor: Hospital General de Mexico
Overall Status: Active - Recruiting

Phase

N/A

Condition

Alcohol Use Disorder

Alcohol Dependence

Treatment

Study Cohort

Clinical Study ID

NCT06589973
606023-01-1624
  • Ages 18-80
  • All Genders

Study Summary

The goal of this observational study is to describe the impact measured through the Odds Ratio (OR) of different variables of clinical and biochemical alterations on the duration of the syndrome alcohol withdrawal patients measured in days of symptoms and stay; it could include any patients with a diagnosis of admission of alcohol withdrawal syndrome (AWS) who have been treated in the department of Internal Medicine for 5 years.

The main question it aims to answer is: What is the relationship between the different clinical, biochemical, and hematic factors on the duration of symptoms, morbidity, and mortality in individuals with alcohol syndrome withdrawal?

• If the patient has a greater number of risk factors, such as advanced age, a long and chronic history of alcohol consumption, the type of distillate consumed, as well as the deterioration of liver function and presence of leukocytosis and neutrophilia, then it is postulated that the duration of alcohol withdrawal syndrome will be longer.

Clinical records will be used to describe the proportion of complications associated with alcohol withdrawal syndrome including pneumonia bronchial aspiration, seizures, need for mechanical ventilation, digestive tract hemorrhage, toxic-alcoholic hepatitis, and pancreatitis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Clinical records of patients, both genders, over 18 years of age with AlcoholWithdrawal Syndrome according to the criteria for alcohol withdrawal.

  • Clinical records of candidates for admission for neurological monitoring and withcriteria for use of sedative drugs according to the CIWA-Ar scale

  • Clinical records of patients containing the CIWA-Ar scale score at diagnosis

Exclusion

Exclusion Criteria:

  • Clinical records of patients who already have a history of seizures or epilepsy

  • Clinical records of diabetic patients with diabetic ketoacidosis

  • Clinical records of patients who have not received any type of sedative treatment

  • Clinical records of patients with chronic liver failure or liver cirrhosis

  • Clinical records of patients with chronic liver disease with signs of hepaticencephalopathy

  • Clinical records of patients with related toxic-alcoholic hepatitis

  • Clinical records of patients with a life expectancy of less than 24 hours due toassociated complications such as head trauma or other associated complications

  • Clinical records of patients who require intubation and mechanical ventilation uponadmission

  • Clinical records of patients who have a vascular event that modifies theneurological evaluation

  • Clinical records of patients who before admission show psychomotor alteration orneurological deterioration that modifies the neurological evaluation such as thepresence of Wernicke's encephalopathy

Study Design

Total Participants: 195
Treatment Group(s): 1
Primary Treatment: Study Cohort
Phase:
Study Start date:
September 09, 2024
Estimated Completion Date:
February 28, 2025

Study Description

Clinical records (files) of patients with a diagnosis of admission of alcohol withdrawal syndrome (AAS) who have been treated in the Department of Internal Medicine for 5 years.

Connect with a study center

  • Hospital General de Cuautitlan "General José Vicente Villada"

    Mexico City, 54800
    Mexico

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.